COVID-19 Vaccine Efficacy: New Insights into Class Switch of IgG Antibodies

Strategic Insights -

Researchers from the NMI Natural and Medical Sciences Institute at the University of Tubingen have made a significant breakthrough in understanding the response of the immune system to COVID-19 vaccines. Their study, recently published in the International Journal of Infectious Diseases, reveals that the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines elicit distinct subclass responses of IgG antibodies against SARS-CoV-2. The study's findings have significant implications for our understanding of long-term immunity and protection against severe disease.

Key Takeaways:

  • The Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines induce different subclass responses of IgG antibodies against SARS-CoV-2.
  • The study found that IgG2 and IgG4 levels were significantly higher in BNT162b2 than in mRNA-1273 vaccinees.
  • Individuals who had previously received a non-mRNA vaccination showed no significant increase in IgG2 and IgG4 post-boost.
  • The research identified vaccine-specific differences post-booster vaccination, which may drive the class switch between IgG2 and IgG4 responses.
  • The study concluded that the subtle differences in subclass responses may ultimately affect long-term immunity and protection.

Statistics:

  • The study analyzed a healthy cohort of 165 individuals who had received two previous vaccine doses.
  • The research found that boosting increased all subclass IgG levels, except for S1-specific IgG1 and S2-specific IgG2.
  • The Pfizer-BioNTech (BNT162b2) vaccine induced significantly higher levels of IgG2 and IgG4 antibodies against SARS-CoV-2 compared to the Moderna (mRNA-1273) vaccine.

Sources:

  • International Journal of Infectious Diseases
  • NewsRx publication, "Research Results from NMI Natural and Medical Sciences Institute at the University of Tubingen Update Understanding of COVID-19 (Class switch toward IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees)"